The research company Chosa Oncology announces that the company’s international patent application under the PCT has been published. The application covers a predictive method that, using biological information from tumors, will predict treatment response for the combination of platinum-based chemotherapy and PD-(L)1 immunotherapy.The aim is to improve patient selection and reduce trial-and-error in clinical treatment decisions. No financial details are provided. Patents are very important for companies such as Chosa Oncology. "The publication of this international patent application under the PCT is an important step in building a globally relevant intellectual property position in patient selection for combination therapies with platinum and PD-(L)1 inhibitors," says Chosa Oncology's CEO Peter Buhl Jensen. "It strengthens our ability to pursue partnerships and commercial opportunities in global oncology markets," he continues.